Loading resource…

null
Meropenem is a widely prescribed β-lactam antibiotic known for its pharmacodynamic efficacy when administered continuously. This randomized clinical trial, known as the MERCY trial, aims to determine whether continuous infusion provides better outcomes compared to intermittent dosing in terms of all-cause mortality and the emergence of drug-resistant bacteria. The findings suggest no significant difference in the primary outcomes between the two administration methods.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

VASOPRESSORS OR FLUIDS IN EARLY SEPTIC SHOCK
Same clinical topic · Critical Care Medicine

LOWER VS HIGHER FLUID VOLUMES IN ADULT PATIENTS WITH SEPSIS - AN UPDATED SYSTEMATIC REVIEW WITH META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS
Same clinical topic · Critical Care Medicine

INTERNATIONAL ANALGESIA AND SEDATION WEANING AND WITHDRAWAL PRACTICES IN CRITICALLY ILL ADULTS: THE ADULT IATROGENIC WITHDRAWAL STUDY IN THE ICU
Same clinical topic · Critical Care Medicine

HEPARIN-INDUCED THROMBOCYTOPAENIA
Same clinical topic · Critical Care Medicine

WHEN AND HOW MUCH? STEROIDS IN SEPSIS
Same clinical topic · Critical Care Medicine

THE ACID-BASE EFFECTS OF ALBUMIN IN SEPSIS: RECONCILING THE STEWART PHYSICOCHEMICAL APPROACH WITH THE TRADITIONAL BUFFER-BASE PARADIGM
Same clinical topic · Critical Care Medicine

Intubation in the Critically Ill: When, How, and How Long?
Same clinical topic · Critical Care Medicine

STATE - OF - THE - ART REVIEW: ß - BLOCKADE IN CRITICAL ILLNESS
Same clinical topic · Critical Care Medicine

STATE - OF - THE - ART REVIEW: ß - BLOCKADE IN CRITICAL ILLNESS
Same clinical topic · Critical Care Medicine